Ailux Appoints Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer
* Dr. Miller will lead the advancement of the company's AI-native biologics toward first-in-human trials, with initial clinical entry targeted for 2027 * He will also establish a U.S. clinical and research site to complement the company's research capabilities in Shanghai and the U.K. SHANGHAI...
XtalPi Debuts Kodexia™, the World's First Closed-Loop siRNA Platform Combining Generative AI with First-Principles Modeling
* This unified platform integrates sequence design, chemical modification, experimental validation, extrahepatic delivery design, and intellectual property strategy into an integrated computational–experimental workflow, pioneering in vivo efficacy prediction models to accelerate drug developme...
XtalPi and Fangda Carbon Deploy Predictive AI to Optimize Cost and Material Efficiency in Graphite Electrode Manufacturing
* The jointly developed AI model has passed comprehensive acceptance testing and is now operating within Fangda Carbon's production workflow. * By forecasting performance and screening formulations before physical trials, the system meets cost optimization targets while enabling rapid evaluat...
XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain
* This milestone marks the first IND submission from XtalPi's proprietary pipeline, recently unveiled in its interim results, validating the company's AI and robotics-driven drug discovery platform and its transition to a clinical-stage organization. * Preclinical data demonstrate sub-nanomol...
XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program
* Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. * Viva-Thera combines its first atomic-resolution MPER-TMD-CT structure with XtalPi's AI and automation platform to advance a small-molecule PCC. ...
XtalPi Holdings Announces 2026 Interim Results
SHENZHEN, China, Aug. 19, 2026 /PRNewswire/ -- Financial Highlights: * In the first half of 2026, the Group recorded revenue of RMB393.6 million, compared with RMB517.1 million in the corresponding period of last year. The change was primarily attributable to the high base in the correspondin...
XtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR Target
BOSTON and SHENZHEN, China, June 10, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, today announced a strategic partnership with a prominent international biopharmaceutical company. The collaboration focuses on develo...
XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies
BOSTON, May 29, 2026 /PRNewswire/ -- XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical company DoveTree Medicines Unus Inc. has achieved substantial progress, and that XtalPi has received the second...
Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer
* Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading tozorakimab from preclinical research through Phase 3 investme...
XtalPi Holdings Announces Full Year 2025 Annual Results
HONG KONG, March 25, 2026 /PRNewswire/ -- Financial Highlights: * Revenues for year 2025 were RMB802.6 million, representing a year-over-year increase of 201.2%. * Net profit for year 2025 reached reached RMB 134.6 million, while adjusted net profit amounted to RMB 258.2 million, making th...
XtalPi Holdings Limited to Announce 2025 Annual Results on March 25, 2026
CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- XtalPi Holdings Limited ("XtalPi", or the "Company") (HKEX: 2228), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced that it will report its annual results for t...
Leading Automation Capabilities of XtalPi Recognized by Global Chemical Giant - Successful Launch of Advanced Automated Workstation at BASF
SHANGHAI, Feb. 9, 2026 /PRNewswire/ -- Chemistry serves as the foundational pillar of material innovation and transformation. It supports and shapes almost every aspect of modern industries. Recently, XtalPi Inc. (2228.HK), a global leader in AI- and robotics driven research and development (R&D)...
XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision
* Global thought leaders presented cutting-edge research at the 2026 International Symposium on Molecular Glue Drug Discovery. * XtalPi unveils the AI-driven XGlue™ platform to enable rapid, closed-loop molecular glue drug discovery. * Cross-sector discussions emphasized the need for bridgin...
XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development
SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company ("Lilly") to accelerate the discovery and...
XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals
SHENZHEN, China, Sept. 9, 2025 /PRNewswire/ -- XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 c...
XtalPi Holdings Announces 2025 Interim Results
SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: * Revenue surged 404% year over year to RMB 517 million in the first half of 2025. * Adjusted net profit reached RMB 141 million, marking the company's first-ever half-year profitability. * XtalPi wa...
XtalPi Holdings Announces 2025 Interim Results
SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: * Revenue surged 404% year over year to RMB 517 million in the first half of 2025. * Adjusted net profit reached RMB 141 million, marking the company's first-ever half-year profitability. * XtalPi wa...
XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
CAMBRIDGE, Mass., Aug. 20, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based o...
XtalPi Holdings Limited to Announce 2025 Interim Results on August 27, 2025
CAMBRIDGE, Mass., Aug. 18, 2025 /PRNewswire/ -- XtalPi Holdings Limited ("XtalPi", or the "Company") (HKEX: 2228), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced that it will report its interim results for t...
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration
Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and...
